港股異動丨德視佳漲4.64% 與香港醫思醫療合作擴大在華業務
格隆匯11月5日丨次新股德視佳(1846.HK)漲4.64%,報10.38港元,成交3845萬港元,總市值33億港元。德視佳是首家在港股上市的德國眼科醫療企業。德視佳主營業務是提供視力矯正服務,目前在中國有6家診所,均分佈在一線和新一線城市。10月30日,德視佳集團成員與香港醫思醫療成員集團訂立備忘錄,確立將於香港成立一家合資公司發展眼科服務及相關業務的意向,雙方將各持擬合資企業50%權益。在上市後不久便宣佈與香港醫思醫療集團成立合資公司,也反映出德視佳對中國視力矯正市場的重視程度。據智研諮詢發佈的《2018-2024年中國眼科市場分析預測及發展趨勢研究報告》數據顯示,預計至 2021 年眼科市場規模或將達到1594億元,複合年增長率預計可維持在13.90%,是全球增長最快速的眼科市場之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.